Matthew Phillippe
Executive Vice President, Head of Investor Relations
Replay available
NewAmsterdam Pharma Company N.V. (NAMS) Q1 2026 Earnings Call
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) Q1 2026 earnings conference call, held 2026-05-07. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Michael Davidson
Chief Executive Officer
John Kastelein
Chief Scientific Officer
Tyler Van Buren
Analyst, TD Cowen
Dennis Staying
Analyst, Jefferies
Jarwei Feng
Analyst, Citigroup
Yanon Zhu
Analyst, Wells Fargo
Sebastian Vanderskoot
Analyst, Kempen
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Newamsterdam Pharma Company N.v..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.198 Good day, everyone. My name is June and I will be your conference operator today. 00:00:05.198 -- 00:00:10.305 At this time, we would like to welcome you to the new Amsterdam Prevail update call. 00:00:10.305 -- 00:00:14.490 All lines have been placed on mute to prevent any background noise. 00:00:14.490 -- 00:00:17.855 After the speaker's remarks, there will be a question and answer session. 00:00:17.855 -- 00:00:22.321 If you would like to ask a question during this time, and if you have joined via the 00:00:22.321 -- 00:00:27.247 webinar, please use the raised hand icon, which can be found at the bottom of your webinar 00:00:27.247 -- 00:00:32.433 application. At this time, I would like to turn the call over to Matthew Phillippe, Executive 00:00:32.433 -- 00:00:36.355 Vice President, Head of Investor Relations. 00:00:36.958 -- 00:00:40.582 Thank you, and good morning, everybody. Thanks for joining our call today. 00:00:40.582 -- 00:00:45.608 I'm excited to have Michael Davidson, CEO, John Kastelein, Chief 00:00:45.608 -- 00:00:49.893 Scientific Officer, and Ian Samaya, our Chief Financial Officer, on the call today. 00:00:49.893 -- 00:00:55.860 The presentation we'll be discussing is available on our investor site, 00:00:55.860 -- 00:01:00.703 so please feel free to access it there. However, before we begin, I let Michael share 00:01:00.703 -- 00:01:05.250 some exciting news. I would like to remind everyone and direct everyone to slide two 00:01:05.250 -- 00:01:09.096 and remind that this call will contain forward-looking statements within the meaning 00:01:09.096 -- 00:01:14.123 of federal securities law. These statements may include but are not limited 00:01:14.123 -- 00:01:18.871 to those related to potential clinical benefit...